Clinical studies implementing glutamate neurotransmission in mood disorders.
Emerging evidence suggests that the amino acid neurotransmitter systems are associated with the pathophysiology and treatment of mood disorders. Recent advances in the areas of molecular neurobiology, pharmacology, and magnetic resonance spectroscopy (MRS) now provide better tools to probe the function of the amino acid neurotransmitter systems and are affording us the opportunity to better investigate the relationship of these systems to mood disorders. Here we review the available literature in the field and suggest a possible pathophysiological model that may account for the many of the findings.
Sanacora
Gerard
G
Department of Psychiatry, Yale University, School of Medicine, New Haven, Connecticut 06519, USA. gerard.sanacora@yale.edu
Rothman
Douglas L
DL
Mason
Graeme
G
Krystal
John H
JH
D000818:Animals; D001923:Brain Chemistry / Q000502:physiology; D003863:Depression / Q000378:metabolism / Q000503:physiopathology; D005971:Glutamates / Q000502:physiology*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D019964:Mood Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D017470:Receptors, Glutamate / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D005971:Glutamates; D017470:Receptors, Glutamate; D005680:gamma-Aminobutyric Acid